Data were originally collected from clinical trial NCT number NCT01598298, “A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer: SWOG S1202.” Here, CYP19A1 is linked to breast cancer.